Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pabolizumab plus radiotherapy vs concurrent chemoradiotherapy as neoadjuvant treatment for advanced mid/low rectal cancer
ChiCTR2100045988Phase 2Recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab in rectal cancer (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Tumor regression grading. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2100045988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045988.